第一财经·2025-12-18 09:31Core Viewpoint - The article highlights the successful results of two Phase III clinical studies conducted in China, demonstrating the efficacy and safety of a new diabetes medication, Masitide, developed jointly by Chinese and American pharmaceutical companies [1] Group 1: Clinical Research Findings - The studies confirmed that Masitide outperformed both placebo and Dulaglutide in controlling blood sugar levels and promoting weight loss [1] - Masitide also showed improvements in various cardiovascular metabolic, liver, and kidney-related indicators [1] Group 2: Drug Development Collaboration - Masitide is a dual receptor agonist for glucagon (GCG) and glucagon-like peptide-1 (GLP-1), co-developed by Innovent Biologics from China and Eli Lilly from the United States [1]